Comparative Insights into Native and Allograft BK Polyomavirus Nephropathy: Clinical and Pathological Perspectives from a Matched Cohort Study

Highlight

• Native-kidney BK polyomavirus nephropathy (BKPyVN) presents with higher viral loads and more severe tubulointerstitial injury than allograft BKPyVN.
• Tubular basement membrane (TBM) C4d deposition is frequent in native kidneys affected by BKPyVN, correlating with viral activity.
• Patients with native-kidney BKPyVN have poorer short-term renal outcomes, including lower 12-month ESRD-free survival compared to allograft BKPyVN.
• Delayed diagnosis due to lack of routine BKPyV surveillance in native kidneys likely contributes to worse outcomes, supporting the need for earlier BKPyV testing and timely biopsy in high-risk patients.

Study Background

BK polyomavirus nephropathy (BKPyVN) is a significant cause of kidney graft dysfunction and loss among kidney transplant recipients (KTRs). While extensively studied in the allograft setting, the disease’s clinical and pathological characteristics in native kidneys, especially among non-KTRs or recipients of other organ transplants, remain insufficiently characterized. Given the increasing use of immunosuppressive therapies in diverse transplant populations, understanding BKPyVN’s impact outside kidney allografts carries important clinical relevance. Native-kidney BKPyVN may have distinct pathobiology and clinical trajectories, influencing management strategies and prognostication.

Study Design

This retrospective matched cohort study aimed to delineate the clinicopathological and virological features of native-kidney BKPyVN and compare these with allograft BKPyVN cases. Nine patients presenting with native-kidney BKPyVN were identified, predominantly following hematopoietic stem cell transplantation (6 patients), with the remainder having undergone lung or heart-lung transplantation (3 patients). These individuals exhibited progressive renal dysfunction prompting kidney biopsy. Diagnosis was confirmed with immunohistochemical staining for SV40 large T antigen (SV40-T) and supported by BKPyV DNA detection in urine and/or plasma. A control group of kidney transplant recipients with biopsy-confirmed allograft BKPyVN was established at a 1:4 ratio, matched to demographic and clinical parameters. Clinical data, plasma and urine BKPyV DNA levels, histopathologic evaluation including tubular basement membrane (TBM) C4d immunostaining, and renal outcomes over 12 months were analyzed.

Key Findings

Virological Features: All native-kidney BKPyVN patients had marked BKPyV viruria at diagnosis, with 8 out of 9 demonstrating detectable plasma BKPyV DNA, indicating active systemic viral replication. Compared with allograft BKPyVN controls, native-kidney BKPyVN cases exhibited significantly higher plasma BKPyV DNA levels and greater intrarenal viral load, suggesting a more aggressive infectious process.

Pathological Observations: Kidney biopsies revealed pronounced tubulointerstitial injury in native kidneys, which was more severe than in allograft BKPyVN. Notably, TBM C4d staining was frequently observed in native BKPyVN cases (8 of 9 patients) and correlated positively with the extent of SV40-T antigen positivity, implicating complement activation or immune-mediated injury within the tubular basement membrane region. This finding expands the understanding of immune complement involvement in BKPyVN pathology beyond allograft rejection settings.

Clinical Outcomes: Kaplan-Meier survival analysis demonstrated significantly worse 12-month end-stage renal disease (ESRD)-free survival among native-kidney BKPyVN patients compared to allograft BKPyVN (p=0.001). This indicates a more fulminant disease course and poorer renal prognosis when BKPyVN arises in native kidneys.

Implications for Surveillance and Diagnosis: The greater severity and poorer outcomes associated with native-kidney BKPyVN likely reflect delayed recognition, as routine BKPyV monitoring protocols commonly utilized in kidney transplantation are typically absent in other transplant populations or native kidney disease contexts. This delay underscores the clinical need for earlier BKPyV testing, including BKPyV DNA quantification in plasma and urine, as well as consideration of early kidney biopsy in high-risk patients exhibiting unexplained renal dysfunction.

Expert Commentary

BKPyVN is a recognized complication predominantly characterized in kidney allograft recipients; this study provides valuable insights into its manifestation in native kidneys. The findings that native kidneys can sustain higher viral loads and more severe tubulointerstitial injury suggest significant differences in host-virus interactions between the native and transplanted kidney milieu. The frequent detection of TBM C4d in native kidneys is intriguing, potentially reflecting complement-mediated damage that might be targeted therapeutically in future.

Limitations of this study include its retrospective design and relatively small sample size, inherent to the rarity of native-kidney BKPyVN diagnosis. Additionally, the heterogeneity in transplant backgrounds and immunosuppressive regimens among native-kidney BKPyVN patients might influence the observed differences. However, the matched cohort design strengthens comparative validity. Further prospective studies focusing on early detection strategies and therapeutic interventions tailored to native-kidney BKPyVN are warranted to improve patient outcomes.

Conclusion

This matched cohort study highlights the distinct clinical and pathological profile of native-kidney BK polyomavirus nephropathy compared to allograft involvement. Native-kidney BKPyVN is characterized by higher viral burden, extensive tubulointerstitial damage, frequent TBM C4d deposition, and substantially worse short-term renal survival. These observations emphasize the critical need for heightened clinical vigilance, routine BKPyV surveillance, and prompt kidney biopsy in appropriate patients to facilitate earlier diagnosis and management. Recognizing native-kidney BKPyVN as a clinically significant entity may refine transplant medicine practices and inform future therapeutic research.

Funding and ClinicalTrials.gov

No specific funding details were reported in the reference article. The study appears investigator-initiated and retrospective, with no registered clinical trial number provided.

References

1. Wu T, Yang S, Hong L, He X, Wang Q, Wang J, Jiang Z, Huang Z, Lu D, Huang G, Chen W. Native Versus Allograft BK Polyomavirus Nephropathy: A Matched Cohort Study of Clinicopathological Features and Outcomes. Clinical Transplantation. 2026 Sep;40(9):e70693. PMID: 42767667.
2. Nickeleit V, Singh HK, Mihatsch MJ. Polyomavirus nephropathy in renal transplantation—diagnosis, pathogenesis, and treatment. Current Opinion in Nephrology and Hypertension. 2000;9(6):593-598.
3. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK Virus Nephropathy in Renal Transplant Recipients: Role of Immunosuppression Regimens. Transplantation. 2005 Jul 15;80(1):123-130.
4. Ginevri F, Caillard S, Cesaro S. Management of BK polyomavirus infection in transplant recipients: an update. Pediatric Transplantation. 2017;21(8):e13059.